In a study by Miglietta et al., the possible survival differences according to HER2-low evolution from primary to recurrent breast cancer were exploratively analyzed, and no significant impact on post-recurrence survival (PRS) of either HER2-low concordance or discordance was observed (32). This evidence concerns the gene ERBB2 and breast cancer.